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Abstract
Aim: To evaluate the effect of infliximab induction therapy on calprotectin levels in patients
with ulcerative colitis (UC).
Patients and Methods: In this prospective study 53 patients with active UC from 17 centers were
treated with infliximab therapy (5 mg/kg) at baseline, week 2, and week 6. Faecal calprotectin
was measured every week. Sigmoidoscopies were performed at baseline, week 6 and week 10.
Results: Median calprotectin levels decreased from 1260 (IQR 278.5- 3418 ) at baseline to 72.5
(IQR 18.5 - 463) at week 10 (pb0.001). After 10 weeks, infliximab therapy induced endoscopic
remission and a decrease in calprotectin tob50 mg/kg or at least a 80% decrease from baseline
level in 58% of patients.nt.be (M. De Vos).
European Crohn's and Colitis Organisation. Published by Elsevier B.V. All rights reserved.
558 M. De Vos et al.A significant and steep decrease of calprotectin levels was seen at week 2 for patients with an
endoscopic remission at week 10 as compared to patients who did not show a remission.
(pb0.001).
At week 10 an excellent correlation was found between endoscopic remission and clinical Mayo
score reflected by an AUC of ROC analyses of 0.94 (0.87-1) and with calprotectin measurements
(AUC 0.91 (0.81-1)) : all patients with calprotectin levels b50 mg/kg, and a normal clinical Mayo
score (=0) were in endoscopic remission.
Conclusions: Infliximab induces a fast and significant decrease of faecal calprotectin levels in
anti-TNF naïve patients with ulcerative colitis predictive for remission of disease
© 2011 European Crohn's and Colitis Organisation. Published by Elsevier B.V. All rights reserved.1. Introduction
Although the role of TNF-alpha in the pathogenesis of ulcera-
tive colitis has been debated, Infliximab has been proven to
be effective for the induction and maintenance of clinical re-
mission and mucosal healing, resulting in a corticosteroid-
sparing effect.1,2 In most of the studies and in daily practice,
the clinical Mayo score is used to monitor the disease activity
of ulcerative colitis. It is a scoring system including stool fre-
quency, rectal bleeding and physician's global assessment.
Since one third of the points is attributed to “physician's global
assessment”, the Mayo score is partly subjective. Mucosal
healing defined by the absence of lesions is more objective
and the ultimate goal of therapy but necessitates an endosco-
py. Non-invasive markers including acute phase reactants like
C-reactive protein (CRP) and hematological markers as eryth-
rocyte sedimentation rate (ESR) or albuminemia are cheap,
repeatable but are often normal in mild to moderate ulcera-
tive colitis.
Calprotectin is a neutrophil derived 36 kDa calcium and zinc
binding protein which can bemeasured in the stools. It is a very
sensitive marker for inflammation in the gastrointestinal tract.
Detection of calprotectin levels in stools is easy and very safe:
it requires only minimal quantity of faeces, it is stable for more
than one week at room temperature, is resistant to degrada-
tion, can be analyzed by a simple ELISA test.
Its value as marker for endoscopic and histological activ-
ity has been tested previously3–5 and it was suggested that
it could predict relapses in UC.6,7 Recently its use as predic-
tor for response to first or second line medical therapy has
been suggested8 but not confirmed in another study.9
The present study aimed at evaluating the evolution of cal-
protectin levels under infliximab induction therapy and its
correlation with mucosal healing as compared to Mayo score.2. Patients and methods
2.1. Patients
Anti-TNF naïve patients with active UC from 17 Belgian centers
were treated with infliximab therapy (5 mg/kg) at baseline,
week 2, and week 6. According to the Belgian reimbursement
criteria, patients were eligible for treatment with infliximab
if they had a combined Mayo score of N/=6 including an endo-
scopic subscore of N/=2 despite adequate treatment with ami-
nosalicylates and corticosteroids /immunosuppressive therapyfor at least 3 months. Patients were evaluated at baseline,
week 2, week 6 and week 10 by clinical Mayo score, question-
naire and lab testing (including CRP, erythrocyte sedimenta-
tion rate, albumin, hemoglobin, platelet count). Faecal
calprotectin was measured every week. Sigmoidoscopies were
performed at baseline, week 6 and week 10 and graded from
0 to 3 according to the Mayo endoscopy subscore. Endoscopic
remission was further defined by a score of 1 or less.
Remission per protocol was defined as endoscopic remis-
sion AND a normalization of calprotectin levels (b50 mg/kg)
or at least a 80% decrease from baseline at week 10.
Patients on corticosteroids had to be treated with stable
doses at least 2 weeks before the start of the study and if pos-
sible steroids were tapered from week 2 at fixed schedule.
This study was approved by the local ethical committees
and patients signed informed consent.
2.2. Determination of faecal calprotectin
Every week, patients provided a small (typically a teaspoon)
stool sample (1 g) in a plastic Container. Samples were frozen
at −20 °C within 48 h.
If patients provided a stool sample at the same time point
as the endoscopy, the sample was delivered immediately
prior to the start of the bowel cleansing.
Faecal samples were collected with a disposable, breakable
inoculation loop and entered into a disposable screw cap tube.
The faeces weight was measured and the loop handle broken
off, leaving the loop and 4–6 cm of the handle inside the
tube. Extraction solution containing urea and citrate was
added. After 30 sec agitation on amixer followed by homogeni-
zation for 20 min at 1400 rpm on a shaker, 1 ml of the homoge-
nate was transferred to an Eppendorf tube and centrifuged for
20 min at 10000 ×g. The supernatant (0.5 ml) was collected and
analyzed immediately or frozen at −20 °C for later analysis.
Calprotectin levels were measured on the supernatant by
enzyme linked immunosorbent assay (ELISA) (PhiCal ELISA
kit, Eurospital Kit (SCIMEDX)) with standards and controls in-
cluded and performed according to the manufacturer's in-
structions. Calprotectin levels were measured by a single
central lab. Physicians were blinded for the results throughout
the entire study.
2.3. Statistical analysis
For descriptive analysis, proportions, means and medians
were calculated. Correlations between dichotomous outcome
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culation of area under the curve (AUC) of receiver operator
curves (ROC) with 95% confidence intervals (CI).
Analyses (intention to treat analysis=ITT) are based on the
total number of patients including all available data and assum-
ing missingness at random: for the calculation of proportions of
remission, a regression based multiple imputation was per-
formed including all recorded variables; for the evaluation of
calprotectin titers over time, Linear mixed models analysis
was used; the calculation of repeatedmeasurements ROC anal-
ysis was performed after the calculation of predicted probabil-
ities with GEE modeling. Apart a complete case analysis,
further depicted with an asterisk (*), was added based on the
data from patients completing the study and patients who
stopped the study due to inefficacy (considered as non-
responders). Based on estimates from the literature, the sam-
ple size of this study was calculated in order to have N80%
power to observe a significant decrease of calprotectin levels
under effective UC therapy. All analysis were performed with
PASW/SPSS18, Chicago, ill.3. Results
Fifty-three patients were included. Mean disease duration
was 6 years, and the mean age was 45 years, there were
48% female. Other baseline disease characteristics are men-
tioned in Table 1.Table 1 Demographics and baseline characteristics.
Disease duration Mean 6 years
(0–26)
Age Mean 45 years
(18–78)
Gender 48% Female
Extent of disease (% proctitis, % left sided,
% extensive colitis)
Initial extent 30%–51%–19%
Maximal extent 6%–61%–33%
Current extent 13%–64%–23%
Smoking behavior (current,
ex-, non-smoker)
4%–43%–53%
Current Medication
Mean number 2.4 (1–5)
Oral 5-ASA 83%
Topical 5-ASA 38%
Any ASA 87%
Oral corticoids 66%
Topical corticoids 7.5%
Any corticoids 68%
Methotrexate 2%
Azathioprine 47.2%
Clinical Mayo score (mean+range) 6.3 (0–9)
Endoscopic subscore
­ Mayo score 1 0%
­ Mayo score 2 48%
­ Mayo score 3 52%3.1. Attrition
After 10 weeks, 2 patients stopped therapy due to ineffica-
cy: corticosteroids were started in 1 patient; 1 patient
underwent total colectomy. Three patients stopped due to
safety reasons: 2 allergic reactions, 1 patient had a vertebral
fracture.
Additionally, 12 patients had missing data, mostly due to
withdrawal consent for endoscopy at the week 10. Those pa-
tients were excluded from complete case analysis, further
depicted with an asterisk (*).3.2. Induction of remission under infliximab therapy
After 10 weeks infliximab therapy induced endoscopic remis-
sion in 63% (CI: 47–78%)* of patients. When all 53 patients
were analyzed with multiple imputation, this overall remis-
sion rate decreased to 59% (CI: 46–72%).
Similarly, when the predefined definition of remission
was used (Colonoscopy b/= grade 1 and, decrease of faecal
calprotectin with 80% or faecal calprotectin levels b50 mg/
kg), 58%* (CI:43–73%) remission was obtained by complete
case analysis and 54% (CI:41–67%) by ITT analysis with multi-
ple imputation. There was no difference in baseline Mayo
score between responders and non responders in Mayo
score (mean 6.5 vs. 6.4), Calprotectin levels (mean 1710
vs. 1680 mg/kg) and endoscopic scores (median 2 vs. 2),3.3. Evolution of calprotectin levels under
infliximab therapy
Median calprotectin levels decreased from 1260 mg/kg (IQR
278–3418)* at baseline to 72.5 mg/kg (IQR18,5-463)* at
week 10. Further analysis showed that patients who went
in endoscopic remission at week 10 showed a significant
steep decrease between baseline and week 2 (pb0.001)
compared to patients who did not show a remission
(Beta=0.7, 95% CI 0.27-1.12). From week 3 on, this course
was more flattened (Fig. 1). In this figure all available data
from all patients were included. The line gives the result of
the Linear mixed model analyses which was used to calculate
the p-values.
The effect of Infliximab was similar in patients with and
without concomitant use of corticosteroids (Fig. 2).3.4. Predictive value of week 2 calprotectin mea-
surements to predict week 10 remission
The steep decrease in calprotectin at week 2 predicted a re-
mission at week 10. However remission was not complete at
week 2 since calprotectin level of 50 mg/kg or a decrease of
at least 80% at week 2 predicted an endoscopic remission at
week 10 with a specificity of 67%* and sensitivity of 54%*. An
additional effect was seen from second and to a less extent
third infusion.
Absence of decrease in calprotectin levels at week 2 iden-
tified patients resistant to the treatment.
Figure 1 Evolution of calprotectin levels under infliximab therapy in function of the induction of endoscopic remission at week 10.
Legend: Boxplots describe medians and interquartile ranges of the completersLines show the result of the mixed models analysis
(ITT analysis).
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variables with endoscopic remission at the moment
of endoscopy
Clinical Mayo score (=0) and calprotecin measurements
(b50 mg/kg) showed an excellent correlation with endoscopic
remission, reflected by an AUC of ROC analyses of 0.94 (0.87-
1) for Mayo score and 0.91 (0.81-1) for calprotectin measure-
ments at week 10*: All patients (63%*) with a calprotectin
level of b50 mg/kg, and all patients (63%*) with a normal clin-
ical Mayo score (=0) were in endoscopic remission. This was
significantly better than the IBDQ and serological parameters
(Table 2). Similar results were obtained with an ITT repeated
measures analysis taking into account all available endoscopicFigure 2 Evolution of calprotectin levels under infliximab ther-
apy in function of the induction of endoscopic remission at week
10 and concomitant use of corticosteroids. Legend: Boxplots de-
scribe medians and interquartile ranges of the completers. Lines
show the result of the mixed models analysis (ITT analysis).results : 0.97 (0.94-1) for the Mayo score and 0.85 (0.77-0.92)
for the calprotectin measurements. Sensitivities and specific-
ities of the different cut-offs of this analysis are provided in
Table 2.
A similar correlation between calprotectin measurements
and remission (AUC=0.89 (0.82-0.97)) was observed when
remission was defined as a total sum score (Mayo and endo-
scopic score) less than 2 with no individual scores ofN1).
3.6. Overall correlation between calprotectin
measurement and clinical Mayo scores
The overall correlation and agreement between calprotectin
measurements and the clinical mayo scores ranged from 0.3
to 0.45, depending on the used statistical method (Spears-
man's rho, Pearson r, Kappa), suggesting that both methods
might be useful to combine in a classification model:
1. Combined measurement at the moment of colonoscopy :
A model combining both clinical Mayo score and calprotectin
measurement as continuous variables, calculated by logisticTable 2 Results of ROC analyses exploring the correlation
between the different variables and endoscopic remission
at week 10.
AUC SE P-value Lower
Bound
Upper
Bound
Mayo.10 (low) 0.94 0.04 0.00 0.87 1.00
Calprotectin (low) 0.91 0.05 0.00 0.81 1.00
IBDQ.10 (high) 0.73 0.08 0.03 0.57 0.89
Album.10 (high) 0.67 0.09 0.09 0.50 0.85
ESR.10 (low) 0.65 0.10 0.15 0.45 0.85
CRP.10 (low) 0.64 0.10 0.18 0.45 0.83
HB.10 (high) 0.56 0.10 0.56 0.36 0.76
PLT.10 (low) 0.53 0.11 0.80 0.31 0.74
561Calprotectin under infliximab therapy in ulcerative colitis patientsregression analysis resulted in a small improvement in its
correlation with endoscopic remission compared to the sin-
gle measurements (AUC of ROC analysis 0.98 (.95-1.00) vs
0.97 (0.94-1.00) for the Mayo score and 0.85 (0.77-0.92)
for the calprotectin measurements).2. Combined measurement at week 2 to predict remission at week 10
A model combining both week 2 clinical Mayo score and week
2 calprotectin measurement as continuous variables, calcu-
lated by logistic regression analysis resulted in a small im-
provement in its correlation with endoscopic remission at
week 10 compared to single measurements (AUC of ROC
analysis 0.77 (0.59-0.95) vs 0.73 (0.53-0.93) for week 2 Mayo
score and 0.59 (0.38-0.79) for week 2 calprotectin
measurements).
4. Discussion
In this prospective study infliximab induction therapy in-
duced a complete endoscopic remission AND a decrease of
calprotectin levels to less than 50 mg/kg or at least a 80%
decrease from start levels in 58% of UC patients with active
disease.
Although it is very well known in Crohn's disease that
infliximab is associated with a rapid clinical effect and de-
crease in CRP levels already observed after 2 weeks,10 the
effect in UC is less well- known. In ACT1 and 2 studies clinical
improvement was observed as early as week 2.1 Similarly in
our study we demonstrated a very fast effectiveness of
treatment with a significant decrease of faecal calprotectin
levels already observed 2 weeks after the first infusion
.However an additional effect of second (and third) infusions
was observed since value of 50 mg/kg or a decrease of at
least 80% at week 2 predicted an endoscopic remission at
week 10 with a specificity of 67% and a sensitivity of 54%.
Retrospective studies have been published in order to pre-
dict responders and included decrease in CRP level at week
2,11 age at diagnosis or treatment or pANCA/ASCA status.12
In children with severe ulcerative colitis faecal concentra-
tions of osteoprotegerin (decoy receptor for RANKL and reg-
ulator of apoptosis and cell survival) at day 3 have been
identified as predictors for use of second line therapy.13 In
adults with severe acute colitis calprotectin levels were
higher in those requiring colectomy and were even useful
to predict response to first and second line medication.8
Similar to ACT1 and ACT2 studies mucosal healing at
8 weeks was observed in 63% of patients. In our study muco-
sal healing (0–1) also was always associated with clinical re-
mission and vice versa clinical Mayo score=0 was always
associated with mucosal healing. In contrast mean partial
Mayo score was still 2–3 in ACT1 and ACT2 studies correlat-
ing with a remission in only 28 – 39% of patients. We have
no explanation for this difference but our finding was sup-
ported by a similar association with calprotectin levels of
50 mg/kg or less.
Blood laboratory measurements were less reliable to
evaluate endoscopic remission.
In conclusion, infliximab induces a fast and sharp de-
crease in calprotectin levels already after the first infusion.
The absence of this decrease seems to identify a group ofnon-responders . Calprotectin b50 mg/kg is a very good pre-
dictor for mucosal healing and can possibly be used as addi-
tional for marker for deep remission.Conflict of interest
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